Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits
2022 · Scientific Reports · 65 citations
https://doi.org/10.1038/s41598-022-06306-4
C
Christoph Gorgulla
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
53
Papers
1.4K
Citations
15
h-index
17
i10-index
Christoph Gorgulla is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Computational Drug Discovery Methods & SARS-CoV-2 and COVID-19 Research & Protein Structure and Dynamics. The author has an h-index of 15, co-authored 46 publications.
ORCID: 0000-0001-6986-5270Papers by this author
worksTargeting ROS production through inhibition of NADPH oxidases
2023 · Nature Chemical Biology · 49 citations
https://doi.org/10.1038/s41589-023-01457-5
Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors
2025 · Nature Biotechnology · 48 citations
https://doi.org/10.1038/s41587-024-02526-3
A systematic approach to identify host targets and rapidly deliver broad-spectrum antivirals
2022 · Molecular Therapy · 9 citations
https://doi.org/10.1016/j.ymthe.2022.02.015
Chemically Motivated Simulation Problems are Efficiently Solvable by a Quantum Computer
2024 · arXiv (Cornell University) · 3 citations
https://doi.org/10.48550/arxiv.2401.09268
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat